Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5419]

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical...

Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA

Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer ( Prof Bradley Monk - University of Arizona College of Medicine, Phoenix, USA )

Cabozantinib in combination with atezolizumab in patients with mCRPC

Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty...

Cabozantinib in combination with atezolizumab in patients with mCRPC ( Prof Neeraj Agarwal - University of Utah School of Medicine, Salt Lake CIty, USA )

OncoAlert and ecancer - ESMO 2021 Day 2

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer - ESMO 2021 Day 2 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Long-term outcomes and complications in cancer patients who have recovered from...

Dr David Pinato - Imperial College London, London, UK

Long-term outcomes and complications in cancer patients who have recovered from COVID-19 ( Dr David Pinato - Imperial College London, London, UK )

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast...

Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom

6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer ( Prof Helena Earl - University of Cambridge, Cambridge, United Kingdom )

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or...

Prof Thomas Powles - Queen Mary University of London, London, UK

Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa ( Prof Thomas Powles - Queen Mary University of London, London, UK )

ESMO President: What to watch for at ESMO 2021

Prof Solange Peters - ESMO President

ESMO President: What to watch for at ESMO 2021 ( Prof Solange Peters - ESMO President )

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant...

Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma ( Prof Solange Peters - Lausanne University Hospital, Lausanne, Switzerland )

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and...

Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM ( Dr Enrique Ocio - Marqués de Valdecilla University Hospital, Santander, Spain )

Multidisciplinary management of ovarian germ cell tumours - a single...

Dr Sandip Ganguly - Tata Medical Center, Kolkata, India

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India ( Dr Sandip Ganguly - Tata Medical Center, Kolkata, India )

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or...

Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients ( Prof Sagar Lonial - Winship Cancer Institute of Emory University, Atlanta, USA )

Should every transplant eligible NDMM patient receive a transplant?

Prof Morie Gertz - Mayo Clinic, Rochester, USA

Should every transplant eligible NDMM patient receive a transplant? ( Prof Morie Gertz - Mayo Clinic, Rochester, USA )

More from ecancer